在有效的直接口服抗凝剂治疗下,生物假体大动脉血栓形成
Arda Guler1, Yunus Emre Erata1, Sinem Aydin2
1Department of Cardiology, University of Health Sciences, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.
Echocardiography (Mount Kisco, N.Y.)
|June 26, 2023
概括
接受直接口服抗凝剂 (DOACs) 的生物假体大动脉患者仍然可能发展出血栓. 仔细监测和个性化抗凝剂管理对于预防并发症和膜退化至关重要.
科学领域:
- 心脏病学 心脏病学
- 生物材料科学 生物材料科学
背景情况:
- 过导管手术增加了生物假体门的使用.
- 对这些门的最佳抗血栓管理仍在争论中.
研究的目的:
- 报告生物假体大动脉血栓的病例,尽管有效的直接口服抗凝剂 (DOAC) 治疗.
- 为了突出管理生物假体门患者抗凝剂的复杂性.
主要方法:
- 一个73岁的男性患有生物假体大动脉的病例报告.
- 患者接受了阿皮克萨班治疗,并出现了移动性血栓和早期膜退化.
- 治疗包括切换抗凝血药物.
主要成果:
- 在生物假体大动脉中检测到移动性血栓和早期退行.
- 在改变抗凝剂治疗后发生了血栓回归.
- 一个持久的高梯度表明正在进行的早期膜退化.
结论:
- 在生物假体患者的抗凝剂管理需要仔细注意.
- 尽管有越来越多的证据表明DOACs存在,但密切跟踪是必不可少的.
- 这一案例强调了需要最佳策略来预防血栓栓塞事件和膜退化.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
11
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
11
Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
567
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
567
Venous Thrombosis I: Introduction
14
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
14
Aortic Regurgitation III: Medical Management
26
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
26


